Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the phase 2 PANAMO trial
抗 C5a 抗体 vilobelimab 治疗对重症 COVID-19 患者炎症和凝血生物标志物的影响：第 2 期 PANAMO 试验的子研究
期刊:Respiratory Research
影响因子:6.6
doi:10.1186/s12931-022-02278-1
Endry H T Lim, Alexander P J Vlaar, Lieuwe D J Bos, Lonneke A van Vught, Anita M Tuip-de Boer, Romein W G Dujardin, Maria Habel, Zhongli Xu, Matthijs C Brouwer, Diederik van de Beek, Sanne de Bruin; Amsterdam UMC COVID-19 Biobank Investigators
